BioMarin Pharmaceutical Inc. (BMRN)

94.93
NASDAQ : Health Technology
Prev Close 94.93
Day Low/High 0.00 / 0.00
52 Wk Low/High 75.81 / 106.74
Avg Volume 977.10K
Exchange NASDAQ
Shares Outstanding 178.06M
Market Cap 16.59B
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

BioMarin Promotes Amy Wireman To Group Vice President, Human Resources

BioMarin Promotes Amy Wireman To Group Vice President, Human Resources

SAN RAFAEL, Calif., Dec.

BioMarin Pharmaceutical Becomes #1 Most Shorted Nasdaq 100 Component, Replacing Henry Schein

BioMarin Pharmaceutical Becomes #1 Most Shorted Nasdaq 100 Component, Replacing Henry Schein

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

BioMarin Pharmaceutical Becomes #2 Most Shorted Nasdaq 100 Component, Replacing Hasbro

BioMarin Pharmaceutical Becomes #2 Most Shorted Nasdaq 100 Component, Replacing Hasbro

The most recent short interest data has been released for the 10/31/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Nasdaq 100 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

BioMarin And Believe Limited Announce The Debut Of 'Hemophilia: The Musical'

BioMarin And Believe Limited Announce The Debut Of 'Hemophilia: The Musical'

First-of-its-Kind Musical Featuring 25 High-School Students Affected by Bleeding Disorders Premieres in Broadway Theater

BioMarin To Participate In Two Investor Conferences In November

BioMarin To Participate In Two Investor Conferences In November

- Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ

BioMarin Highlights Breadth Of Innovative Development Pipeline At R&D Day On November 7th In New York

BioMarin Highlights Breadth Of Innovative Development Pipeline At R&D Day On November 7th In New York

Vosoritide for Achondroplasia: Demonstrates Continued Increased Growth through 42 months in Phase 2; Global Phase 3 Fully Enrolled

BioMarin To Highlight Breadth Of Innovative Development Pipeline At R&D Day On November 7th In New York

BioMarin To Highlight Breadth Of Innovative Development Pipeline At R&D Day On November 7th In New York

Key Research & Development Pipeline Products and Data to be Presented, Including:

BioMarin Announces Third Quarter 2018 Results

BioMarin Announces Third Quarter 2018 Results

- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion

BioMarin And Believe Limited Announce Selection Of 25 High School Students To Perform In First-of-its-Kind 'Hemophilia: The Musical'

BioMarin And Believe Limited Announce Selection Of 25 High School Students To Perform In First-of-its-Kind 'Hemophilia: The Musical'

The young adults, each affected by a bleeding disorder, will perform in the Broadway-style musical upon completion of the 'Breaking Through!' Musical Theater Intensive workshop

Forbes Names BioMarin Among World's Best Employers

Forbes Names BioMarin Among World's Best Employers

Company listed amongst top five biotech employers

BioMarin To Participate In Two Investor Conferences In October

BioMarin To Participate In Two Investor Conferences In October

Cantor Fitzgerald Global Healthcare Conference on October 1 in New York City

BioMarin Announces 20 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism (SSIEM) Symposium 2018

BioMarin Announces 20 Poster Presentations At Society For The Study Of Inborn Errors Of Metabolism (SSIEM) Symposium 2018

Updated results from Phase 1/2 program for tralesinidase alfa (formerly BMN 250)

BioMarin To Participate In Three Investor Conferences In September

BioMarin To Participate In Three Investor Conferences In September

- Citi's 13th Annual Biotech Conference on September 5-6 in Boston

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ASPS, BMRN, CNHI, GTIM, JHX, NXEOU, PICO, USAP, VTSI, WUBA Downgrades: ABCB, CTRP, FDP, GBLI, MHLD, PDLI, SMCI, TV Initiations: BHF, PLXP Read on to get TheStreet Quant Ratings' detailed report:

3 Biotech Stock Favorites to Bet on Today: Top Analysts

3 Biotech Stock Favorites to Bet on Today: Top Analysts

Follow the experts. These biotech stocks have Wall Street's best analysts getting bullish.

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop

It is all about perception, and here are strong names to pick up on market weakness.

BioMarin Announces Second Quarter 2018 Results

BioMarin Announces Second Quarter 2018 Results

- Total Revenues of $372.8 million in the Quarter

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

Charts: BioMarin Pharmaceutical Could Rise 30% From Here

I have not seen a bullish breakout from a large base pattern in a while.

BioMarin Paces a Very Strong Biotech Group

BioMarin Paces a Very Strong Biotech Group

Here's how BMRN's chart looks after its blistering gains.

Chart of the Day: BioMarin Pharmaceutical

BMRN is pacing the very strong biotech group.

Probing the Long Side of BioMarin

Probing the Long Side of BioMarin

Latest surge boosts chances of breakout in shares of BioMarin.

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

BioMarin Pharmaceutical Is Doing Better but Patience Is Needed

The upswing is welcomed but it still is not an important breakout of the two-year sideways pattern.

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Stealth Rally: Cramer's 'Mad Money' Recap (Thursday 5/10/18)

Take one part great earnings and one part tremendous skepticism, add in low inflation and you end up with this astonishing stealth rally. Jim Cramer explains it.

What to Expect From Trump's Speech on Drug Prices on Friday

What to Expect From Trump's Speech on Drug Prices on Friday

Since taking office, President Trump has talked big on reining in drug prices, but the administration's lack of action leaves most expecting a May 11 speech that tastes like a nothing burger.

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer and our other experts discus China and tariffs, the 10 year nearing 3%, technical analysis, and biotech stocks.

TheStreet Quant Rating: C- (Hold)